Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT086 IgM concentrate in severe community acquired pneumonia
2010-022380-35Phase 2Completed
- Sponsor
- Biotest AG
- Start
- Feb 2011
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in community-acquired pneumonia (CAP) comparing BT086 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Ventilator-free days. Started Feb 2011; status: completed.
02
Drugs
trimodulin
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2010-022380-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022380-35.